文献リスト

1) Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709-17

2) Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309-21

3) Zannad F, McMurray JJ, Krum H, et al; the EMPHASIS-HF Study Group. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med. 2010 Nov 14. [Epub ahead of print]

4) Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004; 351: 33-41

5) Makhanova N, Hagaman J, Kim HS, et al. Salt-sensitive blood pressure in mice with increased expression of aldosterone synthase. Hypertension. 2008; 51: 134-40

6) Pratt JH. A not-so-modest proposal that a “modest" increase in aldosterone causes hypertension and more. Hypertension. 2008; 51: 39-40

7) Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, et al. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pres-sure. FASEB J. 2010; 24: 2454-63

8) Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990; 82: 1730-6

9) Beygui F, Collet JP, Benoliel JJ, et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation. 2006; 114: 2604-10

10) Güder G, Bauersachs J, Frantz S, et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation. 2007; 115: 1754-61

11) Lieb W, Larson MG, Benjamin EJ, et al. Multi-marker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study. Circulation. 2009; 119: 37-43

12) Velagaleti RS, Gona P, Levy D, et al. Relations of biomarkers representing distinct biological pathways to left ventricular geometry. Circulation. 2008; 118: 2252-8, 5p following 8

13) Tomaschitz A, Pilz S, Ritz E, et al. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J. 2010; 31: 1237-47

14) Shibata S, Nagase M, Yoshida S, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008; 14: 1370-6

15) Iwashima F, Yoshimoto T, Minami I, et al. Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology. 2008; 149: 1009-14

16) Wu X, Tu X, Joeng KS, et al. Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell. 2008; 133: 340-53

17) Qin W, Rudolph AE, Bond BR, et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res. 2003; 93: 69-76

18) Garnier A, Bendall JK, Fuchs S, et al. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation. 2004; 110: 1819-25

19) Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005; 111: 3025-33

20) Ambroisine ML, Favre J, Oliviero P, et al. Aldosterone-induced coronary dysfunction in transgenic mice involves the calcium-activated potassium (BKCa) channels of vascular smooth muscle cells. Circulation. 2007; 116: 2435-43

21) Gómez AM, Rueda A, Sainte-Marie Y, et al. Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. Circulation. 2009; 119: 2179-87

22) Lin Z, Murtaza I, Wang K, et al. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc Natl Acad Sci U S A. 2009; 106: 12103-8

23) Jeong Y, Chaupin DF, Matsushita K, et al. Aldosterone activates endothelial exocytosis. Proc Natl Acad Sci U S A. 2009; 106: 3782-7

24) Michea L, Villagran A, Urzua A, et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats. Hypertension. 2008; 52: 295-300

25) Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol. 2002; 161: 1773-81

26) Nishiyama A, Yao L, Nagai Y, et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension. 2004; 43: 841-8

27) Shibata S, Nagase M, Yoshida S, et al. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension. 2007; 49: 355-64

28) Leopold JA, Dam A, Maron BA, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007; 13: 189-97

29) Stehr CB, Mellado R, Ocaranza MP, et al. Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. J Hypertens. 2010; 28: 2120-6

30) Leroy V, De Seigneux S, Agassiz V, et al. Aldosterone activates NF-kappaB in the collecting duct. J Am Soc Nephrol. 2009; 20: 131-44

31) Matsui H, Ando K, Kawarazaki H, et al. Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. Hypertension. 2008; 52: 287-94

32) Nagase M, Matsui H, Shibata S, et al. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension. 2007; 50: 877-83

33) Mohammed SF, Ohtani T, Korinek J, et al. Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via “nongenomic effects". Circulation. 2010; 122: 370-8

34) Funder JW. The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. Am J Cardiovasc Drugs. 2007; 7: 151-7

35) Funder JW. Is aldosterone bad for the heart？ Trends Endocrinol Metab. 2004; 15: 139-42

36) Mihailidou AS, Loan Le TY, Mardini M, et al. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension. 2009; 54: 1306-12

37) Usher MG, Duan SZ, Ivaschenko CY, et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest. 2010; 120: 3350-64

38) Rickard AJ, Morgan J, Tesch G, et al. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension. 2009; 54: 537-43

39) Leibovitz E, Ebrahimian T, Paradis P, et al. Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction. J Hypertens. 2009; 27: 2192-200

40) Luther JM, Wang Z, Ma J, et al. Endogenous aldosterone contributes to acute angiotensin II-stimulated plasminogen activator inhibitor-1 and preproendothelin-1 expression in heart but not aorta. Endocrinology. 2009; 150: 2229-36

41) Robert V, Heymes C, Silvestre JS, et al. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension. 1999; 33: 981-6

42) Di Zhang A, Cat AN, Soukaseum C, et al. Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension. 2008; 52: 1060-7

43) Lemarie CA, Simeone SM, Nikonova A, et al. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res. 2009; 105: 852-9

44) Albert NM, Yancy CW, Liang L, et al. Use of aldosterone antagonists in heart failure. JAMA. 2009; 302: 1658-65

45) Dietz JD, Du S, Bolten CW, et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension. 2008; 51: 742-8

46) Fagart J, Hillisch A, Huyet J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010; 285: 29932-40

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp